Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program  by Corbacioglu, Selim et al.
Clinical Research: Supportive Care
Deﬁbrotide for the Treatment of Hepatic Veno-Occlusive
Disease: Final Results From the International Compassionate-
Use Program
Selim Corbacioglu 1,*, Enric Carreras 2, Mohamad Mohty 3,4,5, Antonio Pagliuca 6,
Jaap Jan Boelens 7,8, Gandhi Damaj 9, Massimo Iacobelli 10,†, Dietger Niederwieser 11,
Eduardo Olavarría 12, Felipe Suarez 13, Tapani Ruutu 14, Leo Verdonck 15, Robin Hume 16,
Bijan Nejadnik 16,‡, Chinglin Lai 16,‡, Giorgia Finetto 17,§, Paul Richardson 18
1 Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Hospital Regensburg, Regensburg, Germany
2 Spanish Bone Marrow Donor Program, Josep Carreras Foundation, and Josep Carreras Leukaemia Research Institute, Barcelona, Spain
3 Department of Hematology, Hopital Saint-Antoine, Paris, France
4 University Pierre & Marie Curie, Paris, France
5 INSERM UMRs 938, Paris, France
6 Department of Hematology, King’s College Hospital, London, United Kingdom
7 Pediatric Blood and Marrow Transplantation Program, University Medical Center Utrecht, The Netherlands
8 UMC Utrecht, Laboratory of Translational Immunology, The Netherlands
9 Department of Hematology, University Hospital Center of Caen, School of Medicine, France
10 Gentium, Villa Guardia, Italy
11 Department of Hematology and Medical Oncology, University of Leipzig, Germany
12 Blood and Marrow Transplantation Unit, Hammersmith Hospital, London, United Kingdom
13 Department of Hematology, Necker-Enfants Malades University Hospital, Paris, France
14 Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland
15 Isala Clinics, Zwolle, The Netherlands
16 Jazz Pharmaceuticals, Palo Alto, California
17 Jazz Pharmaceuticals, Villa Guardia, Italy
18 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Article history:
Received 1 April 2016
Accepted 4 July 2016
Key Words:
Deﬁbrotide
Compassionate-use program
Stem cell transplantation
Hepatic veno-occlusive disease
Sinusoidal obstruction
syndrome
A B S T R A C T
Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is an unpredictable and
potentially fatal complication of hematopoietic cell transplantation (HCT) or nontransplantation-associated
chemotherapy/radiotherapy. In cases of severe hepatic VOD/SOS, typically deﬁned by associated multiorgan
failure (MOF, also known as multiorgan dysfunction), mortality exceeds 80%. Preclinical and early clinical data
have provided a rationale for deﬁbrotide treatment in hepatic VOD/SOS. Based on this evidence and in rec-
ognition of the dismal prognosis for these patients, deﬁbrotide was made available through an international
multicenter compassionate-use program conducted from December 1998 to March 2009. Physicians partici-
pating in the program voluntarily provided demographic and outcome data for patients given deﬁbrotide. Eﬃcacy
and safety analyses were performed using the data received for 710 treated patients. Deﬁbrotide was given
at 10, 25, 40, 60, or 80 mg/kg/day for a median of 15 days (range, 1 to 119 days). By Kaplan-Meier analysis,
the estimated overall day +100 survival was 54% (58% in the 25 mg/kg/day dose group). Adverse events (AEs)
were reported in 53% of patients. The most common AEs were MOF, progression of hepatic VOD/SOS, sepsis,
and graft-versus-host disease, which were consistent with the AEs expected for this patient population. No
clinically meaningful trends in AEs were identiﬁed by gender, age, or dose group. Safety and eﬃcacy results
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were consistent with prior studies of deﬁbrotide in hepatic VOD/SOS, and subgroup analyses lend support to
the use of the 25 mg/kg/day dose.
© 2016 American Society for Blood and Marrow Transplantation. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
INTRODUCTION
Hepatic veno-occlusive disease, also called sinusoidal ob-
struction syndrome (VOD/SOS), is an unpredictable, potentially
fatal complication of hematopoietic cell transplantation (HCT)
or of nontransplantation-associated chemotherapy/
radiotherapy [1-4]. In severe hepatic VOD/SOS, typically
deﬁned by the presence of multiorgan failure (MOF, also
known as multiorgan dysfunction), the mortality rate may
exceed 80% [3,5].MOF is deﬁned as VOD/SOS along with dys-
function in another major organ system, such as the renal,
pulmonary, or central nervous system (CNS) [1-4]. Clinical-
ly, hepatic VOD/SOS is diagnosed using Baltimore [6] or
modiﬁed Seattle [7] criteria in the absence of other disor-
ders that can cause similar signs and symptoms.
The pathophysiologic cascade in hepatic VOD/SOS in-
volves primary injury to sinusoidal endothelial cells and
stellate cell activation [3,8,9]. This is associated with in-
creases in von Willebrand factor and plasminogen activator
inhibitor type 1, along with decreases in soluble
thrombomodulin and tissue plasminogen activator (tPA)
[10,11]. The sinusoidal lumen narrows because of the depo-
sition of ﬁbrin and cell debris into the space of Disse and
intrasinusoidal coagulation, which causes progressive isch-
emia, hepatocyte dysfunction, and hepatocellular necrosis
[3,8,9]. This narrowing also can lead to postsinusoidal portal
hypertension, hepatorenal syndrome, MOF, and death [3,8,9].
The reported incidence of hepatic VOD/SOS varies, in part
because of the use of different diagnostic criteria, condition-
ing regimens, patient populations, types of transplantation,
and prior therapies. One analysis of data from 135 studies
with a total of 24,920 HCT patients treated between 1979 and
2007 disclosed an overall mean incidence of VOD/SOS of 13.7%
[5]. Severe VOD/SOS may develop in approximately 30% to
50% of these cases, with some reports as high as 77% [5,12].
The analysis of 135 studies also found that the mean inci-
dence of VOD/SOS had increased from 11.5% between 1979
and 1994 to 14.6% between 1994 and 2007, an increase that
may in part be due to changes in HCT populations (eg, ex-
tension of age limits) [5]. Interestingly, the overall increase
seen across studies seems to have occurred despite the re-
duction in incidence observed at certain single centers, such
as a large, expert center [12], which reported a decreased in-
cidence (11.5% using Baltimore criteria from 1985 to 1996
compared with 6.5% from 1997 to 2008). In addition, despite
the use of reduced-intensity conditioning, incidence of hepatic
VOD/SOS was reported to be 2% to 9% in populations receiv-
ing allogeneic HCT [12,13].
Because of the dismal outcomes in hepatic VOD/SOS with
MOF, effective treatments are clearly needed. Deﬁbrotide is
approved in the European Union for the treatment of severe
hepatic VOD/SOS in adults and children ages >1 month who
have undergone HCT and was recently approved by the US
Food and Drug Administration for the treatment of adult and
pediatric patients with hepatic VOD/SOS with renal or pul-
monary dysfunction after HCT [14]. In vitro testing of
deﬁbrotide demonstrated increased tPA and thrombomodulin
and decreased von Willebrand factor and plasminogen ac-
tivator inhibitor type 1 expression, thereby reducing
endothelial cell activation, protecting endothelial cells from
further damage, and augmenting endothelial cell–mediated
ﬁbrinolysis [15-18].
Deﬁbrotide was initially tested in 19 patients with hepatic
VOD/SOS and MOF in 1998; those patients showed a prom-
ising day +100 survival rate of 32% [19]. After the publication
of those early ﬁndings, and in the absence of other effective
therapies, deﬁbrotide was made available to patients with
hepatic VOD/SOS through an international compassionate-
use program (CUP), which was in effect from December 1998
to March 2009. Subsequent to the initiation of the CUP, ad-
ditional studies showed consistent and promising results for
deﬁbrotide treatment of hepatic VOD/SOS with MOF [20-25].
Here, we report the ﬁnal safety and eﬃcacy results for pa-
tients with hepatic VOD/SOSwho received deﬁbrotide through
the CUP.
METHODS
Study Design
This open-label multicenter program provided deﬁbrotide on a
compassionate-use basis or via single-patient emergency investigational new
drug in response to requests from physicians for patients who developed
hepatic VOD/SOS either after HCT or after nontransplantation-associated
chemotherapy/radiotherapy treatment. The CUP was conducted at multi-
ple centers globally (Supplementary Table S1).
There was no oﬃcial protocol for the CUP; physicians requesting
deﬁbrotide through the programwere asked to complete an eligibility screen-
ing form and provide detailed demographic and outcome information on
each patient. Baseline data included age, gender, body weight, primary
diagnosis/disease, date of hepatic VOD/SOS diagnosis, presence of MOF, hep-
atitis B surface antigen and hepatitis C antibody positivity, and aspartate
transaminase and alanine transaminase levels, as well as any hepatic VOD/
SOS prophylaxis/treatment that had been given (eg, tPA, low-molecular-
weight heparin, heparin, ursodiol, prostaglandin E). For patients who
underwent HCT, details about the transplantation (type of donor/graft), date
of transplantation, conditioning regimen, and graft-versus-host disease
(GVHD) prophylaxis (if any) were collected. For patients who did not undergo
HCT, information about the nontransplantation-associated chemotherapy/
radiotherapy regimen and related start date and the diagnosis date were
collected. Requested deﬁbrotide treatment and outcomes data included dosing
information, adverse events (AEs), and survival.
Treating physicians were responsible for requesting use of deﬁbrotide
as an emergency-use investigational drug from the relevant authority (eg,
from the US Food and Drug Administration), securing approval from the ap-
propriate institutional review board, and ensuring that the patient granted
informed consent.
Eligibility Criteria
Inclusion criteria
Patients were required to meet the Baltimore criteria [6] or modiﬁed
Seattle criteria [7] for hepatic VOD/SOS (Table 1). For this study, the Seattle
criteria were further modiﬁed to use a >5%, rather than >2%, weight gain
threshold [4]. Patients were also eligible if they did not meet 2 of the Seattle
criteria but, per the report of the treating physician, had hemodynamic (eg,
hepatic venous pressure gradient), ultrasound, or histologic evidence of
hepatic VOD/SOS.
In the CUP, severe VOD/SOSwas deﬁned as VOD/SOS withMOF or by ≥30%
predicted risk of retrospectively assessed severe hepatic VOD/SOS using the
Bearman model [26]. MOF was deﬁned by renal dysfunction (at least a dou-
bling of creatinine levels from baseline or reduced creatinine clearance from
baseline with or without need for dialysis), respiratory dysfunction (the need
for oxygen supplementation with or without assisted ventilation), or CNS
dysfunction (ie, cerebral failure).
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Potential factors for exclusion
Physicians requesting deﬁbrotidewere asked, at their discretion, to review
patients for the following as potential reasons for not initiating treatment
with deﬁbrotide: hemodynamic instability (regardless of association with
hepatic VOD/SOS and MOF), severe coagulopathy requiring replacement
therapy, GVHD grades 3 or 4, the need for assisted ventilation (not associ-
ated with hepatic VOD/SOS and MOF), loss of consciousness, or receipt of
another investigational drug.
Treatment
When the CUP was initiated, the recommended starting dose of
deﬁbrotide was 10mg/kg/day, administered intravenously in 4 divided doses
over 2 hours each, with titration up to a recommended maximum of 60mg/
kg/day based on tolerability and response. However, based on the 2004
presentation of results from a phase 2 study from the United States [27],
the recommended dose of deﬁbrotide was amended to a ﬁxed 25 mg/kg/
day, in 4 divided doses, each administered over 2 hours. Recommended
treatment duration was a minimum of 14 days (with the ﬁnal decision on
duration at discretion of treating physician), and therapy could be contin-
ued until the patient had a complete response or was discharged from the
hospital.
Key Outcomes Measures
Physicians reported information to regulatory authorities in the context
of their own emergency investigative new drug procedures. Study sites vol-
untarily reported data on outcome formswithout on-site monitoring or query
generation or resolution. Treating physicians were asked to provide outcome
data that included survival status at day +100 after HCT or after
nontransplantation-associated chemotherapy/radiotherapy. Exploratory ef-
ﬁcacy analyses on day +100 survival were conducted for pediatric and adult
patients and subgroups based on dose received, presence of MOF, and
Bearman status (if available), and for the subgroup of patients developing
VOD/SOS after nontransplantation-associated chemotherapy.
Because data were reported by study sites without on-site monitoring
or query generation or resolution, all AEs were considered to be treatment-
emergent, regardless of their temporal relationship to dosing. Exploratory
subgroup analyses were conducted to assess AEs by dose, age, and gender.
Statistical Analysis
Baseline patient demographic and clinical characteristics, exposure to
deﬁbrotide, survival, and AE data (ie, overall, serious, leading to death, leading
to discontinuation) were analyzed for all patients with outcome data who
received at least 1 documented dose of deﬁbrotide. All continuous vari-
ables were summarized using descriptive statistics; categorical variables were
presented as frequencies and percentages for patients with available data.
Survival was estimated by Kaplan-Meier analysis with 95% conﬁdence in-
tervals (CIs). Patients who were alive but were lost to follow-up before day
+100 were censored for survival analyses.
RESULTS
Patients
A total of 1129 patients from 311 sites were provided with
deﬁbrotide. Of these, outcome forms were returned for 710
(63%) who received at least 1 documented dose of deﬁbrotide.
These 710 patients are the subject of the present analysis
(Tables 2 and 3). Most of these patients were ≥18 years (57%)
and acute leukemias were the most common primary dis-
eases (44%) (Table 2). The large majority of patients received
HCT (primarily allogeneic, 71%), and in this HCT cohort, cy-
clophosphamide and busulfan were the most common
conditioning regimens (>40%), whereas cyclosporine and
methotrexate were the most common prophylactic treat-
ments for GVHD (>40%). Hyperbilirubinemia and weight gain
were each observed in >80% of patients. Because the CUP de-
pended on voluntary reporting, not all returned forms
included all requested data.
Exposure
The median daily dose of deﬁbrotide was 25 (range, 10
to 80) mg/kg/day, given for a median of 15 days (range, 1 to
119). Forty-three percent (272) of patients who had avail-
able dosing data received 25 mg/kg/day (Table 4), which is
the approved recommended dose in the European Union and
in the United States.
Premature treatment discontinuation (before theminimum
treatment period) occurred in 197 (28%) patients. The reasons
for discontinuation included AEs (9%), clinical improvement/
resolution (4%), failure/disease progression (3%), death (3%),
consent withdrawn (<1%), other (1%), and reason not re-
ported (9%).
Survival
Across all doses, the Kaplan-Meier estimate of survival at
day +100 after HCT or nontransplantation-associated
chemotherapy/radiotherapy treatment was 54% (95% CI, 50.2
to 58.0) (Figure 1) for the 701 patients with available data.
Of these patients with data, 92 (13%) were alive but lost to
follow-up before day +100 (reasons for loss to follow-up were
not collected by the treating physicians), and their data were
censored in the analysis.
Kaplan-Meier estimates of survival at day +100 were as-
sessed by deﬁbrotide dose group (Figure 2). The day +100
survival estimates by dosage ranged from 43% to 61%. The sur-
vival estimate for patients receiving 25 mg/kg/day, the
approved recommended dose in the European Union and
Table 1
Hepatic VOD/SOS Criteria
Baltimore Criteria [6] Modiﬁed Seattle Criteria [7]
Within 21 days of HCT:
Bilirubin >2 mg/dL plus
2 or more of the following:
Hepatomegaly
Ascites
Weight gain ≥5% of body
weight
Within 20 days after HCT, 2 or more
of the following:
Bilirubin ≥2 mg/dL
Hepatomegaly or upper right
abdominal quadrant pain
Ascites and/or weight gain >2% of
body weight*
* In this study, weight gain was further modiﬁed to >5% [4].
Table 2
Summary of Demographic and Disease Characteristics
Variable Analysis
Population
(N = 710)
Gender
Male 433 (61)
Female 277 (39)
Age at time of HCT or nontransplantation-associated
chemotherapy/radiotherapy treatment, yr
Mean (SD) 26.7 (19.8)
Median (range) 25.0 (.2-70.0)
Age
<18 yr 303 (43)
≥18 yr 407 (57)
Primary disease*
Acute myelogenous leukemia 177 (26)
Acute lymphoblastic leukemia 120 (18)
Myelodysplastic syndrome 46 (7)
Non-Hodgkin lymphoma 43 (6)
Chronic myelogeneous leukemia 43 (6)
Neuroblastoma 32 (5)
Thalassemia 22 (3)
Hodgkin lymphoma 15 (2)
Severe combined immunodeﬁciency 14 (2)
Data presented are n (%), unless otherwise indicated.
* Conditions occurring in ≥2% of patients; data were missing for 25 pa-
tients, and percentages were calculated based on 685 patients with data.
Primary diseases in 1% to 2% of patients were severe combined immuno-
deﬁciency (1.9%), Ewing’s sarcoma (1.7%), multiple myeloma (1.6%),
hemophagocytic lymphohistiocytosis (1.3%), medulloblastoma (1.2%), lym-
phoma not otherwise speciﬁed (1.1%), and chronic lymphocytic leukemia
(1.1%).
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United States [14,28], was 58% (95% CI, 51.1 to 63.5) at day
+100.
Day +100 survival was higher among the subgroups of
pediatric patients (Figure 3), patients without MOF
(Supplementary Figure S1), and in nontransplantation-
associated chemotherapy/radiotherapy patients, compared
with day +100 survival among the overall population (Table 5).
Safety
A total of 378 of 710 (53%) patients reported AEs. Details
regarding relationship to deﬁbrotide and severity were not
available for themajority of the reported AEs; however, causes
of death were frequently reported as AEs and were primar-
ily due to progressive hepatic VOD/SOS with MOF. Therefore,
the vast majority of serious adverse events (SAEs) included
in tabulations were those leading to death, because, by def-
inition, such events met the criteria of seriousness. The
majority of AEs were serious. A total of 364 of 710 (51%) pa-
tients experienced an SAE and 350 of 710 (49%) patients had
a fatal SAE. Withdrawals due to an AE (n = 63 [9%] patients)
were mostly due to hemorrhage (n = 50 [7%] patients), with
gastrointestinal disorders system organ class (SOC) being the
most common (n = 22 [3%]). Of 85 (12%) patients with a re-
ported AE consistent with hemorrhage, the most commonly
affected SOCs were gastrointestinal disorders (n = 33 [5%]);
respiratory, thoracic, and mediastinal disorders (n = 24 [3%]);
vascular disorders (unspeciﬁed site, n = 15 [2%]); and nervous
system disorders (n = 10 [1%]). Serious hemorrhagic AEs oc-
curred in 55 (8%) patients and were fatal in 37 (5%) of these.
The most common fatal hemorrhagic events by SOCs were
respiratory, thoracic, and mediastinal disorders (n = 11 [2%]);
gastrointestinal disorders (n = 9 [1%]); and nervous system
disorders (n = 7 [1%]). Hypotension occurred in 2 (.3%) pa-
tients, both with MOF, and both events were fatal.
There were no clinically meaningful differences ob-
served in overall incidence of AEs or AEs leading to
discontinuation among the deﬁbrotide doses (Table 6). A slight
increase in the incidence of hemorrhagic events was re-
ported with increasing doses, with rates of 11% (10 mg/kg/
day group), 11% (25 mg/kg/day group), 14% (40 mg/kg/day
group), and 15% (60/80 mg/kg/day group). Respiratory-
tract hemorrhage was highest in the 60/80 mg/kg/day dose
group (9%) versus in those on lower doses (<5% each), but gas-
trointestinal and CNS hemorrhages were similar across doses
(4% to 6% and 0 to 2%, respectively). Rates of hemorrhage were
similar in pediatric (13%) and adult (12%) patients.
Gastrointestinal-tract hemorrhage was more common in
adults (6%) than in pediatric patients (3%), and respiratory-
tract hemorrhagewasmore common in pediatric patients (5%)
than in adults (2%). The rate of hemorrhagic AEs in patients
with VOD/SOS andMOF was slightly higher (14%) than in pa-
tients withoutMOF only (11%), and these were predominantly
gastrointestinal (5% for each subgroup). There were no clin-
ically meaningful trends identiﬁed with respect to AEs (ie,
the overall incidence of AEs, SAEs, AEs leading to death, or
discontinuations due to AEs) by gender or age.
Table 3
Initial Treatment and Hepatic VOD/SOS and MOF Characteristics
Characteristic Analysis
Population
(N = 710)
Transplantation* 628 (89)
Allograft 499 (71)
Autograft 112 (16)
Other/not speciﬁed 17 (2)
Nontransplantation*: chemotherapy/radiotherapy
treatment†
79 (11)
Conditioning regimen (>10% of patients)
Cyclophosphamide 369 (52.0)
Busulfan 300 (42.3)
Total body irradiation 209 (29.4)
Antithymocyte globulin 141 (19.9)
Melphalan 134 (18.9)
Fludarabine 124 (17.5)
GVHD prophylaxis
Cyclosporine 403 (57)
Methotrexate 287 (40)
Antithymocyte globulin‡ 105 (15)
Tacrolimus 71 (10)
Mycophenolate mofetil 61 (9)
Prednisone 58 (8)
Other§ 22 (3)
Median time to hepatic VOD/SOS onset,|| d 13
Hepatic VOD/SOS criteria met
Bilirubin >2 mg/dL 623 (88)
Weight gain >5% 584 (82)
Hepatomegaly 548 (77)
Ascites 477 (67)
Right upper quadrant pain 455 (64)
Liver histology 22 (3)
Bearman criteria [26]¶
Severe 337 (48)
Not severe 217 (31)
Not assessed 147 (21)
Missing 9
MOF 292 (41)
Renal# 229 (32)
Dialysis# 41 (6)
Respiratory# 162 (23)
Assisted/mechanical ventilation (associated with
hepatic VOD/SOS)#
37 (5)
Cerebral# 37 (5)
Other** 4 (<1)
No MOF 418 (59)
Data presented are n (%), unless otherwise indicated.
* Transplantation status was missing for 3 patients, with percentages cal-
culated based on patients with data only.
† The most common regimens (in >1% of patients) were vincristine,
cytarabine, gemtuzumab ozogamicin, cyclophosphamide, thioguanine,
etoposide, and actinomycin-B.
‡ Speciﬁed as GVHD prophylaxis only, 141 patients received antithymocyte
globulin as conditioning therapy.
§ Includes T cell depletion, alemtuzumab, and rituximab.
|| After HCT or start of nontransplantation-associated chemotherapy/
radiotherapy treatment, data missing for 15 patients.
¶ Bearman criteria (≥30% risk of retrospectively assessed severe hepatic
VOD/SOS) not assessed for all patients, percentages calculated for patients
with data.
# This criterion meets the deﬁnition of MOF and severe hepatic VOD/
SOS.
** Includes oxygen requirement and intermittent supplemental oxygen.
Table 4
Exposure to Deﬁbrotide in Patients with Dosing Data
Dose
(mg/kg/day)
Age <18 yr
n = 267*
Age ≥18 yr
n = 371*
Total Population
N = 638†
10 22 (8) 63 (17) 85 (13)
25‡ 131 (49) 141 (38) 272 (43)
40 78 (29) 148 (40) 226 (35)
60/80 36 (13) 19 (5) 55 (9)
Data presented are n (%), unless otherwise indicated.
* This number does not include 36 patients for whom dose was not
reported.
† This number does not include the 72 total patients for whom dose was
not reported.
‡ Approved recommended dose in the European Union and in the United
States.
1877S. Corbacioglu et al. / Biol Blood Marrow Transplant 22 (2016) 1874–1882
Consistent with the patient population under study, the
most common AEs were MOF, progression of hepatic VOD/
SOS, sepsis, and GVHD (Table 7).
DISCUSSION
This CUP provided access to deﬁbrotide for patients with
hepatic VOD/SOS with or without MOF after HCT or
nontransplantation-associated chemotherapy/radiotherapy
treatment. The day +100 survival and safety proﬁles in this
study are notably consistent with those reported in other
deﬁbrotide studies [21,23,29].
Consistent with the results of a phase 2 deﬁbrotide dose-
ﬁnding study presented in 2004 and published in 2010 [21]
and also a phase 3 study for eﬃcacy and safety [23], the
current study supports usage of the 25 mg/kg/day dose of
deﬁbrotide (in 4 divided doses, each infused intravenously
over 2 hours). That dose is now approved as the recom-
mended dose in the European Union for the treatment of
severe hepatic VOD/SOS in adults and in children ages >1
month who undergo HCT [28] and in the United States for
the treatment of adult and pediatric patients with hepatic
VOD/SOSwith renal or pulmonary dysfunction after HCT [14].
The median duration of treatment in the CUP was 15 days.
Evidence from other trials suggests there is a beneﬁt of longer
duration of treatment. In the phase 2 study [21], although
the recommendedminimum duration of dosing was 14 days,
the actual median length of treatment was 19 days in the
25 mg/kg/day arm and 20 days in the 40 mg/kg/day arm.
Based on the data from that study, the phase 3 study of
deﬁbrotide recommended that deﬁbrotide be administered
for a minimum of 21 days at a dose of 25mg/kg/day (median
duration of treatment: 21.5 days) [23]. The duration of therapy
that was recommended in the phase 3 study was ≥21 days,
which also was the median duration that was observed. This
shared recommended duration andmedian value was similar
to the observed difference between median time to diagno-
sis (13 days) and median time to onset of complete response
(34.5 days; ie, 34.5 less 13 equals 21.5), as well as the median
Vertical lines signify censored data.
*Excludes 9 patients with missing HCT or nontransplantation–associated chemo-radiotherapy dates.
CI, confidence interval; HCT, hematopoietic cell transplantation.
Figure 1. Survival to day +100 (n = 701).*
Vertical lines signify censored data.
Excludes 9 patients with missing HCT or nontransplantation–associated chemo-radiotherapy dates; 
recommended dose in the European Union and in the United States.
CI, confidence interval; HCT, hematopoietic cell transplantation.
* Approved †
Figure 2. Survival to day +100 by dose (n = 701).*
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Vertical lines signify censored data.
Excludes 9 patients with missing HCT or nontransplantation–associated chemo-radiotherapy dates.
CI, confidence interval; HCT, hematopoietic cell transplantation.
*
Figure 3. Survival at day +100 pediatric patients (n = 303) and adults (n = 407).*
Table 5
Day +100 Survival by Subgroup
Status Alive, n (%)
[95% CI]
Alive When Lost to
Follow-Up, n (%) [95% CI]
Not Alive,
n (%) [95% CI]
With Data
Missing*, n
Kaplan-Meier Estimated
Survival [95% CI]
Analysis population
N = 710
310 (44)
[40.6-47.9]
92 (13)
[10.6-15.6]
299 (43)
[39.0-46.3]
9 .542
[.502-0.580]
Pediatric (<18 yr)
n = 303
149 (50)
[43.9-55.1]
58 (19)
[14.8-23.7]
94 (31)
[26.0-36.4]
2 .654
[.594-0.708]
10 mg/kg/day (n = 22) 9 (41)
[20.4-61.5]
3 (14)
[−.07-28.0]
10 (45)
[24.6-66.3]
0 .511
[.278-0.704]
25 mg/kg/day (n = 131) 68 (52)
[43.4-60.5]
28 (21)
[14.4-28.4]
35 (27)
[19.1-34.3]
0 .702
[.609-0.777]
40 mg/kg/day (n = 78) 36 (47)
[36.3-58.4]
16 (21)
[12.0-30.1]
24 (32)
[21.3-41.9]
2 .653
[.527-0.753]
60/80 mg/kg/day (n = 36) 19 (53)
[36.5-69.1]
8 (22)
[8.6-35.8]
9 (25)
[10.9-39.1]
0 .709
[.513-0.838]
Dose not reported (n = 36) 17 (47)
[30.9-63.5]
3 (8)
[−.7-17.4]
16 (44)
[28.2-60.7]
0 .537
[.359-0.686]
Adult (≥18 yr)
n = 407
161 (40)
[35.5-45.0]
34 (9)
[5.8-11.2]
205 (51)
[46.4-56.1]
7 .461
[.409-0.510]
10 mg/kg/day (n = 63) 22 (36)
[24.2-47.9]
4 (7)
[.4-12.7]
35 (57)
[45.2-69.6]
2 .406
[.279-0.528]
25 mg/kg/day (n = 141) 54 (39)
[30.8-46.9]
15 (11)
[5.7-15.9]
70 (50)
[42.1-58.6]
2 .463
[.375-0.547]
40 mg/kg/day (n = 148) 61 (42)
[34.1-50.0]
13 (9)
[4.4-13.6]
71 (49)
[40.9-57.0]
3 .483
[.396-0.564]
60/80 mg/kg/day (n = 19) 8 (42)
[19.9-64.3]
0 11 (58)
[35.7-80.1]
0 .421
[.204-0.625]
Dose not reported (n = 36) 16 (44)
[28.2-60.7]
2 (6)
[−1.9-13.0]
18 (50)
[33.7-66.3]
0 .471
[.299-0.626]
Severity by MOF
MOF (n = 292) 95 (33)
[27.6-38.4]
27 (9)
[6.0-12.7]
166 (58)
[52.0-63.3]
4 .397
[.338-0.455]
No MOF (n = 418) 215 (52)
[47.3-56.8]
65 (16)
[12.2-19.2]
133 (32)
[27.7-36.7]
5 .647
[.596-0.693]
Bearman criteria
Severe (n = 337) 125 (38)
[32.6-42.9]
28 (8.5)
[5.5-11.4]
178 (54)
[48.5-59.1]
6 .438
[.382-0.493]
Nonsevere (n = 217) 113 (52)
[45.7-59.0]
39 (18)
[12.9-23.2]
57 (37)
[29.4-44.6]
1 .669
[.597-0.731]
Nontransplantation-associated
chemotherapy/radiotherapy
MOF (n = 38) 18 (51)
[35.5-67.3]
6 (17)
[5.2-29.1]
11 (31)
[16.7-46.2]
3 .675
[.489-.806]
No MOF (n = 41) 22 (56)
[41.2-71.6]
8 (21)
[8.2-32.9]
9 (23)
[10.2-36.0]
2 .742
[.560-.858]
* Patients with missing data not included in percentages.
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length of treatment in the phase 2 dose-ﬁnding study [21,23].
Data from an ongoing expanded-access study enrolling pa-
tients with VOD/SOSwith andwithout MOF after HCT or after
nontransplantation-associated chemotherapy have similar-
ly shown a 21-day median duration of treatment (analysis
population) [29], which also was the recommendedminimum
duration of treatment in that study.
The Kaplan-Meier estimated survival rate of 40% in the
CUP for the subgroup of patients with MOF (after HCT or after
nontransplantation-associated chemotherapy/radiotherapy)
is generally consistent with outcomes of other deﬁbrotide
studies in populations with MOF (after HCT), including the
historically controlled phase 3 trial: the observed day +100
survival in post-HCT patients was 38% in the deﬁbrotide group
(n = 102) versus 25% in the historical control group (n = 32)
[23]; the estimated between-group difference in survival was
23% (95.1% CI, 5.2 to 40.8; P = .0109), using propensity-
adjusted analysis. Outcomes were also similar to the phase
2 dose-ﬁnding trial [21].
Similarly, survival results from the CUP in patients with
hepatic VOD/SOS without MOF are comparable to those seen
in the interim analysis of an ongoing expanded-access study
in a similar patient population (dosed at 25 mg/kg/day for a
recommended ≥21 days) [29]. For all 255 patients without
MOF in the expanded-access study interim analysis (en-
rolled from 2007 through 2013), the Kaplan-Meier estimated
survival rate at day +100 was 65% [29], which is consistent
with the CUP Kaplan-Meier estimated survival rate of 65%.
In the CUP, 11% (79 of 710) of patients with VOD/SOS
had received chemotherapy without HSCT. Of those
nontransplantation-associated chemotherapy patients, the
Kaplan-Meier survival rate by day +100 was similar to the
Kaplan-Meier–estimated day +100 survival rates for this sub-
group in the expanded-access study: [30] 71% (95% CI, 58.6
to 80.3) (68% for patients with MOF [n = 38] and 74% for pa-
tients without MOF [n = 41]). In that study, patients in the
nontransplantation-associated chemotherapy subgroup were
mostly pediatric (80%, compared with 58% in the overall
study), and themost prevalent primary diseasewas acute lym-
phocytic leukemia (44%, compared with acute myeloid
leukemia [27%] overall), which may be contributing factors
to increased survival [29,30].
In both the CUP and expanded-access studies, the higher
survival rate in patients without MOF indicates that further
studies are warranted to determine the impact of initiating
treatment earlier in the course of hepatic VOD/SOS.
The incidence of AEs reported in the CUP was generally
consistent with prior trials [21,23,28]. Because of the nature
of the CUP, mild-to-moderate AEs not leading to discontinu-
ation were anticipated to be under-reported and deaths were
likely to be reported. Indeed, the vast majority of reported
AEs were those leading to death. The overall incidence of
serious and fatal events was consistent with published ﬁnd-
ings on VOD/SOS and deﬁbrotide in the treatment of VOD/
SOS, and is as expected for this very ill patient population
[21,23,28]. No clinically meaningful differences were ob-
served for AEs, SAEs, or fatal events by gender, age, or dose
group in this CUP.
Historically, risk of bleeding has been a concern for pa-
tients with VOD/SOS [31]. Other forms of treatment, such as
tPA and heparin, have been associated with hemorrhage and
extensive patient withdrawals from treatment (~50%) [32].
By contrast, the recently published deﬁbrotide phase 3 trial
results show that the incidence of common hemorrhagic AEs
was similar in the deﬁbrotide and control groups (64% versus
75%, respectively) [23], and an earlier phase 3 prophylaxis trial
found cumulative rates of hemorrhage of 22% and 21%, re-
spectively (P = .8176) [33].
This study had some limitations. There was no protocol
for this program and all reporting of patient data and out-
comes was voluntary, without on-site monitoring. As such,
in some cases, outcome forms were either not returned or
not fully completed for all patients, which may have re-
sulted in under-reporting of AEs that did not lead to death.
In addition, the relatively shorter recommended duration of
treatment in this program, comparedwithmore recent studies
also may have inﬂuenced eﬃcacy and safety outcomes.
This CUP includes data on deﬁbrotide use across a long
period of time in a large number of patients (n = 710). The
study included a heterogeneous population of patients with
VOD/SOS, in part because of the real-world nature of the
program and in part because of differences in inclusion
Table 6
Summary of AEs by Dose of Deﬁbrotide
Category of AE Total Population
(N = 710)
Dose (mg/kg/day)
10 (n = 85) 25 (n = 272) 40 (n = 226) 60/80 (n = 55) Unknown (n = 72)
Any AE (≥1) 378 (53) 59 (69) 129 (47) 124 (55) 27 (49) 39 (54)
AE leading to death 350 (49) 56 (66) 120 (44) 113 (50) 24 (44) 37 (51)
SAE 364 (51) 58 (68) 123 (45) 119 (53) 26 (47) 38 (53)
AE leading to discontinuation 63 (9) 7 (8) 23 (8) 25 (11) 4 (7) 4 (6)
AEs of special interest
Hemorrhage event 85 (12) 9 (11) 31 (11) 31 (14) 8 (15) 6 (8)
Hypotension event 2 (<1) 1 (1) 1 (<1) 0 0 0
Data presented are n (%), unless otherwise indicated.
Table 7
AEs Reported in ≥2% of Patients
AE* Analysis Population (N = 710)
All Serious Leading
to Death
MOF, new or worsening 144 (20) 144 (20) 144 (20)
Progression of VOD/SOS 79 (11) 78 (11) 78 (11)
Sepsis 49 (7) 48 (7) 48 (7)
GVHD 28 (4) 28 (4) 28 (4)
Gastrointestinal hemorrhage 19 (3) 10 (1) 7 (1)
Recurrent cancer 15 (2) 15 (2) 15 (2)
Hemorrhage 14 (2) 8 (1) 7 (1)
Pulmonary hemorrhage 14 (2) 12 (2) 9 (1)
Acute myelogenous
leukemia, recurrent
12 (2) 12 (2) 12 (2)
Pneumonia 12 (2) 12 (2) 12 (2)
Septic shock 11 (2) 11 (2) 10 (1)
Data presented are n (%).
* Classiﬁed by Medical Dictionary for Regulatory Activities 16.0; pre-
ferred term by the treating physician.
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criteria in different regions. The safety data are consistent with
reports from controlled trials of deﬁbrotide [21,23,33]. The
CUP also provides valuable information about a range of
deﬁbrotide doses and captures the experience of real-
world deﬁbrotide usage, demonstrating that the beneﬁts
shown in research trials can be achieved in the clinical setting.
CONCLUSIONS
When only supportive care is available, hepatic VOD/
SOS with evidence of MOF has been associated with a fatality
rate of more than 80% by day +100 after HCT [5]. For pa-
tients in this CUP, the Kaplan-Meier estimated day +100
survival rate of 54% in the broad patient population and 40%
in the subgroup with MOF is supportive of a beneﬁcial treat-
ment effect for these critically ill patients and is consistent
with prior studies of deﬁbrotide in VOD/SOS. AEs were likely
under-reported because of the nature of this CUP. Nonethe-
less, the overall proﬁle of serious and fatal events in this large
study population of more than 700 patients was consistent
with what has been observed in other studies of deﬁbrotide
for the treatment of VOD/SOS and was consistent with the
manageable toxicities seenwith deﬁbrotide use in this setting.
Additionally, safety and eﬃcacy subgroup analyses in this
study lend support to the use of 25 mg/kg/day as recom-
mended dosing for deﬁbrotide in VOD/SOS patients.
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